

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/51525239>

# Thailandepsins: Bacterial Products with Potent Histone Deacetylase Inhibitory Activities and Broad-Spectrum Antiproliferative Activities

ARTICLE *in* JOURNAL OF NATURAL PRODUCTS · JULY 2011

Impact Factor: 3.8 · DOI: 10.1021/np200324x · Source: PubMed

---

CITATIONS

38

---

READ

1

7 AUTHORS, INCLUDING:



**Leonhard M Henkes**

Technische Universität Dortmund

7 PUBLICATIONS 77 CITATIONS

SEE PROFILE



**Min He**

National Institutes of Health

11 PUBLICATIONS 163 CITATIONS

SEE PROFILE



**Franz-Josef Meyer-Almes**

Darmstadt University of Applied Sciences

37 PUBLICATIONS 1,155 CITATIONS

SEE PROFILE

# Thailandepsins: Bacterial Products with Potent Histone Deacetylase Inhibitory Activities and Broad-Spectrum Antiproliferative Activities

Cheng Wang,<sup>†</sup> Leonhard M. Henkes,<sup>‡</sup> Leah B. Doughty,<sup>†</sup> Min He,<sup>§</sup> Difei Wang,<sup>⊥</sup> Franz-Josef Meyer-Almes,<sup>‡</sup> and Yi-Qiang Cheng<sup>\*,†,||</sup>

<sup>†</sup>Department of Biological Sciences, and Department of Chemistry and Biochemistry, University of Wisconsin—Milwaukee, P.O. Box 413, Milwaukee, Wisconsin 53201, United States

<sup>‡</sup>Department of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, 64287 Darmstadt, Germany


<sup>§</sup>Developmental Therapeutics Program, the US National Cancer Institute, Frederick, Maryland 21701, United States

<sup>⊥</sup>Laboratory of Cell Biology, the US National Cancer Institute, Bethesda, Maryland 20892, United States

<sup>||</sup>MoE Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, People's Republic of China

**S** Supporting Information

**ABSTRACT:** Histone deacetylase (HDAC) inhibitors have emerged as a new class of anticancer drugs, with one synthetic compound, SAHA (vorinostat, Zolinza; **1**), and one natural product, FK228 (depsipeptide, romidepsin, Istodax; **2**), approved by FDA for clinical use. Our studies of FK228 biosynthesis in *Chromobacterium violaceum* no. 968 led to the identification of a cryptic biosynthetic gene cluster in the genome of *Burkholderia thailandensis* E264. Genome mining and genetic manipulation of this gene cluster further led to the discovery of two new products, thailandepsin A (**6**) and thailandepsin B (**7**). HDAC inhibition assays showed that thailandepsins have selective inhibition profiles different from that of FK228, with comparable inhibitory activities to those of FK228 toward human HDAC1, HDAC2, HDAC3, HDAC6, HDAC7, and HDAC9 but weaker inhibitory activities than FK228 toward HDAC4 and HDAC8, the latter of which could be beneficial. NCI-60 anticancer screening assays showed that thailandepsins possess broad-spectrum antiproliferative activities with GI<sub>50</sub> for over 90% of the tested cell lines at low nanomolar concentrations and potent cytotoxic activities toward certain types of cell lines, particularly for those derived from colon, melanoma, ovarian, and renal cancers. Thailandepsins thus represent new naturally produced HDAC inhibitors that are promising for anticancer drug development.




Epigenetic abnormalities participate with genetic mutations to cause cancer,<sup>1</sup> and consequently epigenetic intervention of cancer has emerged as a promising avenue toward cancer therapy. Selective inhibition of histone deacetylases (HDACs) by small molecules often leads to a cascade of chromatin remodeling, tumor suppressor gene reactivation, apoptosis, and regression of cancer.<sup>2</sup> HDAC inhibitors have thus gained much attention in recent years as a new class of anticancer agents.<sup>2–6</sup> One synthetic HDAC inhibitor, SAHA (vorinostat, Zolinza; **1**), and one natural product HDAC inhibitor, FK228 (depsipeptide, romidepsin, Istodax; **2**), have already been approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma,<sup>7,8</sup> and many more HDAC inhibitors (mostly synthetic molecules) are in various stages of preclinical or clinical trials as single agents or in combination with other chemotherapy drugs for diverse cancer types.<sup>5,9,10</sup>

FK228 is produced by *Chromobacterium violaceum* no. 968.<sup>11,12</sup> It belongs to a small family of natural products that also includes

FR901,375 (**3**),<sup>13</sup> spiruchostatins A (**4**) and B (**5**),<sup>14</sup> thailandepsins A (**6**) and B (**7**) discovered by us<sup>15</sup> (and this article.<sup>15</sup> is a US patent application filed on August 19, 2010 and published online on March 10, 2011, with a priority date of August 19, 2009), and burkholdacs A (**8**) and B (identical to **6**) reported recently by Biggins et al. (appeared online on February 26, 2011).<sup>16</sup> All members of this family of natural products are produced by rare Gram-negative bacteria, and each of them contains a signature disulfide bond that is known or presumed to mediate its anticancer activity via reduction of the disulfide bond to generate a free thiol group (“warhead”) that chelates a Zn<sup>2+</sup> in the catalytic center of class I and class II HDACs, thereby inhibiting the enzyme activities.<sup>17</sup> The biosynthesis of FK228 is proposed to follow a widely accepted “assembly-line” mechanism<sup>18–20</sup> in which simple building

**Received:** April 15, 2011

blocks (amino acids, amino acid derivatives, and short carboxylic acids from primary metabolism) are assembled stepwise by seven modules of a hybrid nonribosomal peptide synthetase (NRPS)-polyketide synthase (PKS) multifunctional pathway to afford a linear intermediate, which is subsequently cyclized by a terminal thioesterase (TE) domain to form an immediate FK228 precursor.<sup>21</sup> An FAD-dependent oxidoreductase is responsible for a disulfide bond formation as the final step of FK228 biosynthesis.<sup>22</sup>



Historically natural products have made tremendous contributions to human medicines.<sup>23,24</sup> Despite the controversial downsizing of natural product-based drug discovery efforts by the pharmaceutical industry in the past two decades, there has been a sign of renaissance of natural product discovery activities in recent years, largely due to new technology advances and unmet need of new drugs for chronic and emerging diseases.<sup>20,25</sup> Genome mining, which takes advantage of the rapid growth of microbial genome sequence information and in-depth understanding of natural product biosynthetic logics, has emerged as an effective new approach for the discovery of molecules encoded in cryptic biosynthetic gene clusters.<sup>26,27</sup>


In this article, we report the discovery of two FK228-analogues, **6** and **7**, from the fermentation broth of a genome-sequenced bacterium, by a combination of several enabling technologies including genome mining and metabolic profiling. Enzyme inhibition assays showed that **6** and **7** are potent inhibitors of human HDACs. NCI-60 anticancer screening<sup>28,29</sup> demonstrated broad-spectrum antiproliferative activities of **6** and **7** against an array of human cancer cell lines. Therefore, **6** and **7** represent new naturally produced HDAC inhibitors that are promising for anticancer drug development.

## RESULTS AND DISCUSSION

**Identification of a Cryptic Biosynthetic Gene Cluster.** The goal of our research is to explore naturally produced and biologically or chemically engineered members of the FK228-family of HDAC inhibitors as new anticancer agents. To this end, we have cloned and characterized a biosynthetic gene cluster (designated *dep* for depsipeptide FK228) and three discrete genes collectively responsible for FK228 biosynthesis in *C. violaceum*.<sup>21,30,31</sup> Those studies provided us the first-hand opportunity to identify a cryptic biosynthetic gene cluster (designated *tdp* for thalidomide) in the published genome of *Burkholderia thailandensis* E264 (GenBank accession no. CP000085 and CP000086)<sup>32</sup> (Figure 1). The genes and their deduced proteins of this *tdp* gene cluster exhibit a significant overall similarity to those of the *dep* gene cluster (Table 1). In particular, the deduced products of eight genes (*tdpA*, *tdpB*, *tdpC1*, *tdpF*, *tdpG*, *tdpH*, *tdpI*, and *tdpJ*) share 67%/80% or higher sequence identity/similarity with their respective counterparts from the FK228 biosynthetic pathway. Like the *dep* gene cluster, this *tdp* gene cluster does not contain any gene that encodes a phosphotransferase (PPTase) necessary for posttranslational modification of carrier proteins<sup>33</sup> or an acyltransferase (AT) necessary for in trans complementing the three “AT-less” PKS modules<sup>34</sup> on TdpB, TdpC1, and TdpC2 proteins. A thorough search of the *B. thailandensis* genome found multiple candidate genes that may encode the missing PPTase or AT activity; experimental verification of the responsible gene (tentatively named *tdp\_sfp* or *tdp\_AT*) is in progress. A few differences between the two parallel gene clusters are identified as follows: (i) Unlike *depR* which is located downstream of the *dep* gene cluster and encodes an OxyR-type transcriptional activator, *tdpR* is located upstream of the *tdp* gene cluster and encodes a putative AraC-type transcriptional regulator. These two deduced regulatory proteins do not have notable sequence homology. (ii) There is no *depM*-equivalent in the *tdp* gene cluster. (iii) There are two copies of a *depC*-like gene in the *tdp* gene cluster, the second copy is fused to DNA encoding a likely inactive epimerase (E) domain and is located after *tdpDE1*. (iv) A *depE*-like gene in the *tdp* gene cluster is split into two parts, the first part is fused to the end of *tdpD*, and the second part is transposed to a downstream location between *tdpG* and *tdpH*. (v) Unlike pseudogene “*depN*”, the deduced protein of *tdpN* appears to be a functional peptidyl carrier protein (PCP) with a critical serine residue for phosphotransferase activity.

Using the FK228 biosynthetic pathway as a reference,<sup>21</sup> we dissected the domain and module organization of six deduced NRPS- and PKS-type enzymes (TdpA, TdpB, TdpC1, TdpDE1, TdpC2, and TdpE2) encoded by the *tdp* gene cluster and proposed a hybrid NRPS-PKS biosynthetic pathway model which also includes three discrete enzymes (AT, TdpF, and TdpH) (Supporting Information Figure S1). This proposed pathway contains eight NRPS/PKS modules responsible for seven consecutive steps of building block polymerization that results in a full-length linear intermediate installed on a PCP domain in the last module. A terminal TE domain is predicted to cleave off the intermediate and subsequently cyclize it into a macrolactam intermediate. Finally an FAD-dependent oxidoreductase (TdpH) is predicted to catalyze a disulfide bond formation as the final step of the biosynthesis of **6** and **7**.

We initially predicted the putative chemical structures of compounds that may be produced by the proposed biosynthetic pathway.



**Figure 1.** Comparison of two homologous biosynthetic gene clusters and discrete genes necessary for the biosynthesis of FK228 (**2**) or thailandepsins A (**6**) and B (**7**). Each gene cluster is depicted in a row, under which is the deduced respective modular biosynthetic pathway. A, ACP, AL, AT, C, DH, E, KR, KS, PCP, and TE are standard abbreviations of the nonribosomal peptide synthetase (NRPS) or polyketide synthase (PKS) domain names whose full name and respective function can be found in Fischbach et al.<sup>18</sup> Sfp and AT are the generic protein names of their respective genes defined in the main text.


**Table 1.** Comparison of Two Homologous Biosynthetic Gene Clusters and Their Associated Discrete Genes Necessary for Product Biosynthesis

thailandepsin biosynthetic ( <i>tdp</i> ) gene cluster		FK228 biosynthetic ( <i>dep</i> ) gene cluster <sup>21,30,31</sup>		percentage ident./ simil. btw prot. seq.	confirmed or deduced protein function <sup>c</sup>
gene <sup>a</sup>	protein <sup>b</sup>	gene <sup>b</sup>	protein <sup>b</sup>		
<i>tdp_sfp</i> (multiple candidates) (discrete) <sup>d</sup>	Tdp_Sfp	<i>dep_sfp</i> (discrete) <sup>d</sup>	Dep_Sfp	--	phosphopantetheinyl transferase (PPTase)
<i>tdp_AT</i> (multiple candidates) (discrete) <sup>d</sup>	Tdp_AT	<i>dep_fabD1</i> , <i>dep_fabD2</i> (discrete) <sup>d</sup>	Dep_FabD1, Dep_FabD2	--	acyltransferase, malonyl CoA-specific (AT)
<i>BTH_I2369</i>	TdpR	--	--	--	AraC-type transcriptional regulator
--	--	<i>depM</i>	DepM	--	aminotransferase
<i>BTH_I2368</i>	TdpN	--	--	--	type II peptidyl carrier protein (PCP)
<i>BTH_I2367</i>	TdpA	<i>depA</i>	DepA	74/83	NRPS (1 module)
<i>BTH_I2366</i>	TdpB	<i>depB</i>	DepB	78/86	PKS (1 module)
<i>BTH_I2365</i>	TdpC1	<i>depC</i>	DepC	76/84	PKS (1 module)
<i>BTH_I2364</i>	TdpDE1	--	--	--	--
--	--	<i>depD</i>	DepD	56/67	NRPS (1 module)
--	--	<i>depE</i>	DepE	39/52	NRPS (1 module)
<i>BTH_I2363</i>	TdpC2	<i>depC</i>	DepC	39/50	PKS (1 module)
<i>BTH_I2362</i>	TdpF	<i>depF</i>	DepF	88/93	FadE2-like acyl-CoA dehydrogenase
<i>BTH_I2361</i>	TdpG	<i>depG</i>	DepG	75/84	phosphotransferase
<i>BTH_I2360</i>	TdpE2	<i>depE</i>	DepE	31/49	NRPS (partial module)
<i>BTH_I2359</i>	TdpH	<i>depH</i>	DepH	72/84	FAD-dependent disulfide oxidoreductase
<i>BTH_I2358</i>	TdpI	<i>depI</i>	DepI	74/84	esterase/lipase
<i>BTH_I2357</i>	TdpJ	<i>depJ</i>	DepJ	67/80	type II thioesterase
--	--	<i>depR</i>	DepR	--	OxyR-type transcriptional regulator

<sup>a</sup> Gene annotations from the GenBank. <sup>b</sup> Gene/protein names designated by the authors. <sup>c</sup> Standard abbreviations: NRPS, nonribosomal peptide synthetase; PKS, polyketide synthase. <sup>d</sup> Detached from the perspective gene cluster; --: not available.

The predicted structures (Supporting Information Figure S1) were slightly different from the experimentally determined ones (**6** and **7**), reflecting the power and yet limitation of in silico analysis.





**Figure 2.** Metabolic profiling of the wild type strain (BthWT) and Bth $\Delta$ tdpAB mutant strain of *B. thailandensis* E264. (a–c) HPLC traces of extract of the medium control, BthWT strain or Bth $\Delta$ tdpAB strain, respectively. (d,e) ESI-LC-MS spectra of the HPLC peak 1 and peak 2 of the BthWT sample (b). (f,g) ESI-LC-MS spectra of the reduced HPLC peak 1 and peak 2 of the BthWT sample (b), showing a +2  $m/z$  shift of every ion signal.

**Discovery of Thailandepsins A (6) and B (7).** We executed a series of experiments to purify and identify two new bacterial products, named thailandepsin A (6) and thailandepsin B (7), from the fermentation culture of *B. thailandensis* E264.

First we identified by semiquantitative reverse transcription (RT)-PCR method several cultivation conditions in which the cryptic *tdp* gene cluster is highly expressed (Supporting Information Figure S2a). We found that two representative structural genes, *tdpA* and *tdpJ*, are expressed at significant levels at 30 °C in five (M1, M2, M3, M8, and M9) of the nine production media tested (Supporting Information Table S1) at the 24 h time point, with the highest level in M9, a modified minimal medium. Furthermore, we found that *tdpA* is expressed at significant levels in the five identified media at all four time points examined, with the highest level in M9 at about 24 h (Supporting Information Figure S2b); the level of *tdpA* expression begins to decrease after 24 h but persists beyond 72 h. Medium M9 was thus selected as the optimal medium for subsequent bacterial fermentation.

We then created a gene-deletion mutant (Bth $\Delta$ tdpAB) and detected metabolic profiling differences between the wild type strain (BthWT) and the mutant strain of *B. thailandensis* E264. We employed a well-established multiplex PCR method<sup>22,35</sup> to create the mutant strain in which a critical segment of the *tdpAB* adjoining region was permanently deleted (Supporting Information Figure S2c). This deletion truncated a part of the adenylation (A) domain and the entire PCP domain of the NRPS module on TdpA and a part of the ketoacyl synthase (KS) domain of the PKS module on TdpB of the thailandepsin biosynthetic pathway (Supporting Information Figure S1). As a result, not only three critical catalytic domains of the pathway have been impaired or deleted by the gene deletion event but also the protein–protein communication between TdpA and TdpB was disrupted. It is thus certain that the entire biosynthetic pathway must have been disabled. Subsequently both BthWT and Bth $\Delta$ tdpAB strains were cultivated in M9. Organic extracts of both bacterial cultures and a medium control were analyzed by high performance liquid chromatography (HPLC) and detected the disappearance of several HPLC peaks in the Bth $\Delta$ tdpAB sample (part c vs b of Figure 2). We anticipated that the corresponding peaks in the BthWT sample could be the target compounds produced by the

cryptic *tdp* gene cluster. Those peaks were collected and examined by electrospray ionization (ESI)-LC-MS.

Importantly, we observed critical chemical properties of the putative target compounds. The material of peak 1 from HPLC yielded a pair of ion signals of 547.9/530.0  $m/z$  (Figure 2d), and the material of peak 2 sample yielded 530.0/511.9  $m/z$  (Figure 2e). It is believed that the higher  $m/z$  signal from each pair is the protonated adduct of a target molecule  $[M+H]^+$ , and the lower  $m/z$  signal is the protonated adduct of a respective target molecule with a  $H_2O$  molecule removed (dehydrated;  $[M-H_2O+H]^+$ ) by heat/electrovoltage (eV) during ESI-LC-MS. Interestingly, when the materials of HPLC peaks were first reduced with DTT and then subjected to ESI-LC-MS analysis, both samples generated ion signals with a +2  $m/z$  mass shift, a polarity shift (more hydrophilic, as judged by an earlier elution time), and a change of the relative abundance of parental molecule/dehydrated derivative (Figure 2f,g). Those observations strongly suggested that we had identified two target compounds that are most likely produced by the cryptic *tdp* gene cluster in *B. thailandensis* under the fermentation conditions tested, and those compounds probably contain a disulfide bond (thus existing as a prodrug) which can be reduced/activated by DTT in the same way as FK228 by DTT.

Finally, we fermented the BthWT strain in large volume in M9, and subsequently purified and identified the target compounds 6 and 7 by natural product chemistry methods including organic extraction, gravity chromatography, preparative HPLC, amino acid analysis, MS, NMR, degradation analysis, and chemical derivatization (see Supporting Information).

**Thailandepsins A (6) and B (7) are New FK228-Class Natural Products.** Compounds 6 and 7 are new chemical entities with distinctive features that belong to the FK228-class of natural products. Both 6 and 7 are bicyclic depsipeptides that contain a 15-membered macrolactam ring and a second 15-membered ring with a signature disulfide bond, whereas FK228 contains a 16-membered macrolactam ring and a 15-membered side ring with a signature disulfide bond. Like FK228,<sup>17,21</sup> the disulfide bond in 6 and 7 is predicted to be reduced inside mammalian cells to generate free thiol groups, of which one thiol group interacts with the  $Zn^{2+}$  inside the catalytic pocket of human

**Table 2.** The Calculated IC<sub>50</sub> Value of Each Compound vs Each HDAC in  $\mu$ M Concentration

inhibitor	enzyme							
	HDAC1	HDAC2	HDAC3	HDAC4	HDAC6	HDAC7	HDAC8	HDAC9
<b>2</b>	6.7	1.5	0.018	>50	12	>50	>50	>50
<b>2</b> <sup>a</sup>	0.0053	0.0039	0.0053	0.47	0.33	3.2	0.026	12
<b>6</b>	7.5	39	0.087	>50	9.9	>50	>50	>50
<b>6</b> <sup>a</sup>	0.014	0.0035	0.0048	42	0.38	11	1.2	12
<b>7</b>	7.7	4.5	0.023	22	11	27	30	>50
<b>7</b> <sup>a</sup>	0.0065	0.0067	0.0094	18	0.61	24	1.0	30

<sup>a</sup> Compounds were reduced/activated prior to being assayed.

**Table 3.** The Influence of Different H<sub>2</sub>O<sub>2</sub> Concentrations on the Potency of FK228 (**2**) against HDAC3/N-CoR2

compd	H <sub>2</sub> O <sub>2</sub> [mM]	enzyme activity [%]	IC <sub>50</sub> [ $\mu$ M]
<b>2</b>	0.0	100.0	0.018
<b>2</b>	0.2	70.8	0.020
<b>2</b>	0.4	68.9	0.039
<b>2</b>	1.0	57.3	0.041

HDACs, thus inhibiting the enzyme's activity, as illustrated by molecular modeling (Supporting Information Figure S8).

From a biosynthetic point of view, it is apparent that both **6** and **7** are composed of building blocks of short carboxylic acids, amino acids, or amino acid derivatives, consistent with the proposed model of a hybrid PKS-NRPS biosynthetic pathway (Supporting Information Figure S1). Compound **6** differs from **7** by having a methionine (Met) moiety, where **7** has a norleucine (NLeu) moiety. According to a comprehensive database of nonribosomal peptides,<sup>36</sup> the simultaneous presence of cysteine (Cys) and Met, two proteogenic amino acids that contain a thiol function, in nonribosomally synthesized **6**, is unprecedented, and **7** appears to be the first natural product reported to contain a nonproteogenic NLeu building block. Overall, **6** and **7** are structurally more similar to **4** and **5** than to **2**. In particular, **6** and **7** only differ from **5** at the Met/NLeu position, where **5** has an alanine (Ala) moiety.

**HDAC Inhibitory Activities of Thailandepsins A (**6**) and B (**7**) Compared to FK228 (**2**).** Because of a striking structural similarity between **6/7** and **2**, we predicted that both **6** and **7** would likely also possess HDAC inhibitory and antiproliferative activities. To test this hypothesis, the inhibitory potency of both the oxidized form (natural, prodrug form with a disulfide bond) and the reduced form (activated form with two free thiol groups, indicated by \*) of **2** (as a reference compound), **6**, and **7** against recombinant human class I HDACs [HDAC1, HDAC2, HDAC3 (in complex with N-CoR2), and HDAC8], class IIa HDACs (HDAC4, HDAC7, and HDAC9), and class IIb HDAC6 was determined by a two-step fluorogenic assay.<sup>37</sup> All HDAC dose–response curves were bundled for each compound individually (Supporting Information Figure S3a,b), and the IC<sub>50</sub> values in  $\mu$ M are summarized in Table 2.


Each of the three compounds in its reduced/activated form (**2**\*, **6**\*, **7**\*) is a much more potent HDAC inhibitor than its natural/oxidized prodrug form (**2**, **6**, **7**). These observations are in agreement with a previous report that an enhanced inhibitory effect of the reference compound **2** was detected after being

reduced with DTT and assayed against HDAC1, HDAC2, HDAC4, and HDAC6.<sup>17</sup>

Reduced thailandepsins **6**\* and **7**\* exhibited a similar ranking of inhibitory potency against human HDACs: HDAC1, HDAC2, and HDAC3 are strongly inhibited at low nanomolar concentrations; inhibition of the distantly related HDAC8 is about 80–350 times weaker than the inhibition of HDAC1–3; HDAC6 is still strongly inhibited but the potency of **2**\*, **6**\*, or **7**\* toward HDAC6 is about 30–100 times less than to HDAC1–3; HDAC4, HDAC7, and HDAC9 are the least inhibited with IC<sub>50</sub> values 3–4 orders of magnitude higher than those for HDAC1–3. It is apparent that all three activated compounds are more potent toward class I HDACs than toward class II HDACs. Thus class I HDACs, particularly HDAC1–3, are the primary targets of inhibition by those natural products.

Interestingly there are significant differential inhibitory effects among **2**\*, **6**\*, and **7**\* on HDAC4 and HDAC8. Both **6**\* and **7**\* are 40–90-fold less potent against HDAC4 or HDAC8 than **2**\*. This difference could be beneficial for drug development. Studies have shown the involvement of HDAC4 in multiple vital cellular regulation mechanisms.<sup>38–41</sup> Although HDAC8 is a member of class I HDACs but by sequence comparison it is far away from the other members (Supporting Information Figure S7), therefore HDAC8 may presumably play a very different biological role than the other members of class I HDACs. Because the toxicity of HDAC inhibitors is often a bigger concern than potency in drug development, and **6**\* and **7**\* are much less inhibitory than **2**\* against HDAC4 and HDAC8, **6**\* and **7**\* may exhibit favorable anticancer or cytotoxicity profiles.

Surprisingly FK228 and thailandepsins in their natural/oxidized prodrug form (**2**, **6**, and **7**) appeared unexpectedly to be strong inhibitors of the HDAC3/N-CoR2 complex with IC<sub>50</sub> values ranging from 18 to 87 nM, whereas they are 80–450 times less active against the closely related HDAC1 and HDAC2. To exclude the potential influence of traces of thiol **2**\* on enzyme inhibition, a series of dose–response curves of **2** in the presence of different concentrations of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) was carried out against HDAC3/N-CoR2 (Supporting Information Figure S3c). Increasing concentrations of the oxidizing agent up to 1.0 mM resulted in decreasing levels of enzyme activity of the HDAC3/N-CoR2 complex in the absence of **2**. However when assayed with **2**, the IC<sub>50</sub> values of **2** remained similarly low (Table 3), indicating that the oxidized form of **2** indeed has pronounced inhibitory activity against the HDAC3/N-CoR2 complex, perhaps by a different mode of action. This seemingly increased susceptibility of HDAC3 might be influenced by its complex with corepressor N-CoR2. Guenther et al.<sup>42</sup> have shown



**Figure 3.** In vitro antiproliferative/cytotoxic activities of thailandepsins A (6) and B (7) in comparison with FK228 (2). (a) Heat map representation of antiproliferative/cytotoxic activities<sup>50</sup> of 6 and 7 across NCI-60 cell lines, with higher activity (lower index value) in warmer colors. GI<sub>50</sub>, growth-inhibition indicator; TGI, cytostatic effect indicator; LC<sub>50</sub>, cytotoxic effect indicator. Compound concentration in M was converted to log<sub>10</sub> value for continuous color scale transformation. Mean panel response values were expressed in  $\mu$ M. (b) Statistics comparison of antiproliferation/cytotoxicity profile between 2, 6, and 7 across NCI-60 cell lines.

that HDAC3 is completely inactive on its own but is activated by forming a stable complex with the nuclear hormone receptor corepressor N-CoR2. Therefore, N-CoR2 is required both for activation of HDAC3 and for its recruitment of other nuclear repressors. It is speculated that the FK228-family of HDAC inhibitors may display their effects either through binding outside of the active site of HDAC3 to its complex with N-CoR2 or by interfering directly with the interaction between HDAC3 and N-CoR2, yielding inactive uncomplexed HDAC3. The concept of disturbing the formation of the HDAC3/N-CoR2 complex could open new routes to selective inhibitors against HDAC3 because the ability of N-CoR2 to activate HDAC is specific to HDAC3.<sup>42</sup>

**In Vitro Antiproliferative/Cytotoxic Activities of Thailandepsin A (6) and Thailandepsin B (7).** Compounds 6 and 7 were submitted to the US National Cancer Institute (NCI)'s Developmental Therapeutics Program (DTP) on August 12, 2009 for screening against the NCI-60 human cancer cell lines<sup>28,29</sup> and were accepted by assigning entry numbers NSC D751510 and NSC D751511, respectively. Both compounds exhibited broad-spectrum antiproliferative activities similar to 2, with GI<sub>50</sub> for over 90% of the tested cell lines at low nanomolar concentrations (Figure 3a). Differential activities toward specific cell lines were observed at the TGI and LC<sub>50</sub> level, particularly for those derived from colon, melanoma, and renal cancers, while leukemia cell lines were generally less sensitive. Matrix Compare analysis showed close correlation in antiproliferation profile between 6, 7, and 2, with Pearson correlation coefficient above 0.7 across the GI<sub>50</sub> and LC<sub>50</sub> levels (Figure 3b). Overall, 2 is slightly more potent at the TGI and LC<sub>50</sub> levels in most cell lines, consistent with its slightly more potent in vitro HDAC inhibitory activity compared with 6 and 7 (Table 2). However, 6 is more potent than 2 or 7 in most cell lines at the GI<sub>50</sub> level, and in certain cell lines at the TGI and LC<sub>50</sub> levels (colon cancer HCC-2998,

melanoma LOXIMVI and UACC-62, and renal cancers A498 and RXF393).

Further in vivo toxicities and efficacies of 6 and 7 are being evaluated in the mouse xenograft models. It remains interesting to see whether 6 and/or 7 could advance to clinical trials or how far they could proceed in the drug development pipeline. For the immediate future, 6 and 7 could be used as valuable epigenetic-intervening reagents for research on cancer or other human diseases.

During the preparation and journal review process<sup>43</sup> of this article, Biggins et al. published a rapid communication of two compounds (named burkholdac A and burkholdac B) discovered from the same bacterial strain produced by the same gene cluster but using a different technical approach.<sup>16</sup> Burkholdac B is identical to 6, while burkholdac A (8) and 7 are different minor products related to 6. Compound 7 is newly reported in this article.

## EXPERIMENTAL SECTION

**Bacterial Strains, Plasmids, and Reagents.** *Burkholderia thailandensis* E264 (ATCC 700388), a Gram-negative  $\beta$ -proteobacterium strain originally isolated from a rice paddy in central Thailand,<sup>44</sup> was purchased from the American Type Culture Collection (ATCC, Manassas, VA). This bacterial strain was cultured in Luria–Bertani (LB) medium or LB agar supplemented with 50  $\mu$ g/mL apramycin (Am; this bacterial strain is naturally resistant to up to 200  $\mu$ g/mL of Am) at 30–37 °C overnight for seed culture and for genetic and molecular manipulations. Other general molecular biological procedures were as described in refs 21 and 45 or in reagent supplier's instruction.

**RT-PCR Detection of Gene Expression Conditions.** RT-PCR for the detection of gene expression conditions of *tdpA* and *tdpJ* was performed as described in the Supporting Information.

**Construction of a Targeted Gene-Deletion Mutant of *B. thailandensis* E264.** A detailed description of the creation of a *Bth*Δ*tdpAB* mutant is described in the Supporting Information.



**Metabolic Profiling by LC-MS.** *B. thailandensis* E264 wild type (BthWT) strain and the Bth $\Delta$ tdpAB mutant strain were cultivated side by side in 50 mL of Medium 9 (M9 in Supporting Information Table S1) supplemented with 1% (w/v) of XAD16 resin and 1% (w/v) of Diaion HP-20 resin (Sigma-Aldrich) at 30 °C for 3 days. A blank M9 was set up as medium reference. At the end of fermentation, resin and cell debris were collected and lyophilized to dryness, and the dry mass was extracted three times with 5 mL of ethyl acetate and pooled. A 100  $\mu$ L aliquot of the ethyl acetate extract was analyzed by HPLC, using an Eclipse XBD C<sub>18</sub> column (5  $\mu$ m particle size, 4.6 mm  $\times$  250 mm; from Agilent) and a gradient elution from 20% to 100% of acetonitrile/water (v/v) in 30 min. Flow rate was set at 1 mL/min and UV signal was monitored at 200 nm. Peaks of interest from the BthWT sample were manually collected, dried, and redissolved in acetonitrile. A 20  $\mu$ L aliquot of such sample was reanalyzed by LC-MS (1100 series LC/MSD Trap mass spectrometer from Agilent). In addition, an equal volume of the sample was reduced with 50 mM DTT at room temperature and reanalyzed by LC-MS.

**Purification and Identification of Thailandepsins A (6) and B (7).** A detailed description of natural product purification and identification is described in Supporting Information.

**Fluorogenic Assays of HDAC Inhibition Activities.** Trypsin (from bovine pancreas), DMSO, and Pluronic were purchased from Sigma-Aldrich (Germany). All reactions were performed in FB-188 buffer (15 mM Tris, 50 mM KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub>, 250 mM NaCl, 250  $\mu$ M EDTA, pH 8.0; from Roth, Germany) supplemented with 0.001% (v/v) Pluronic. The recombinant human HDACs were purchased from BPS Bioscience Inc. (San Diego, CA) and diluted in corresponding buffers. Compounds (**2**, **6**, and **7**) were dissolved in DMSO; half of each was then reduced by tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (CalBioChem, Germany) in a molar ratio of 1:1.5 for 20 min at ambient temperature prior to being assayed. The two-step fluorogenic assay was performed in 96-well half area microplates (Greiner Bio-One, Germany) in a total volume of 100  $\mu$ L according to Wegener et al.<sup>37</sup> In principle, an  $\epsilon$ -acetylated lysine substrate is first deacetylated by an HDAC in a reaction which is subsequently quenched by SAHA (kindly provided by Dr. A. Schwienhorst). Trypsin then is added to the reaction to cleave the detectable 7-amino-4-methylcoumarin (AMC; excitation at 390 nm, emission at 460 nm) off the deacetylated lysine. Fluorogenic signals were detected with a Polarstar fluorescence plate reader (BMG). Blank reactions showed that both DMSO and TCEP inhibit the investigated HDAC activities less than 3% at the highest compound concentration used. Therefore, the influence of solvent or reducing agent on the enzyme activity could be neglected.

Boc-L-Lys( $\epsilon$ -acetyl)-AMC was a suitable substrate (20  $\mu$ M working concentration) for HDAC1, HDAC2, and HDAC6. Boc-L-Lys( $\epsilon$ -trifluoroacetyl)-AMC was successfully used (at 20  $\mu$ M working concentration) for assaying HDAC3, HDAC4, HDAC7, HDAC8, and HDAC9. Both substrates were purchased from Bachem (Weil am Rhein, Germany). Analysis of the data and calculation of the IC<sub>50</sub> values was accomplished using a four-parameter logistic model protocol as previously described.<sup>46</sup> For nonlinear fits, the Levenberg–Marquardt algorithm was applied.<sup>47,48</sup>

**The NCI-60 Anticancer Drug Screen and COMPARE Analysis.** Details of the NCI-60 screening protocol are described online (<http://www.dtp.nci.nih.gov/branches/btb/ivclsp.html>). Screening experiments were conducted using five serial concentrations from 10<sup>-4</sup> to 10<sup>-8</sup> M of each compound. To compare the holistic antiproliferative activities between **2**, **6**, and **7**, the mean values of the GI<sub>50</sub>, TGI, or LC<sub>50</sub> data across all NCI-60 cell lines were calculated from duplicated screening experiments performed for **6** and **7** in the present study, and five historically screening experiments that had been conducted for **2** by the NCI Developmental Therapeutics Program. Mean-graph signatures for all three agents were generated following the procedures described online (<http://dtp.nci.nih.gov/docs/>

compare/COMPARE\_methodology.html) and were used for a matrix COMPARE analysis.<sup>49</sup>

## ■ ASSOCIATED CONTENT

**S Supporting Information.** Methods, results, NMR spectra, structures, assays, and references. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*Phone: (414) 229-4739. Fax: (414) 229-3926. E-mail: [yicheng@uwm.edu](mailto:yicheng@uwm.edu).

## ■ ACKNOWLEDGMENT

We thank D. DeShazer (Walter Reed Army Medical Center) and H. Schweizer (Colorado State University) for providing vector tools, K. Nithipatikom (Medical College of Wisconsin) for assistance with HR-MS analysis, H. Foersterling (University of Wisconsin-Milwaukee) for assistance with NMR analysis, the NCI Developmental Therapeutics Program for conducting NCI-60 anticancer screening, M. Kunkel (NCI-DTP) for assistance with the COMPARE analysis of NCI-60 data, and D. Newman (NCI-DTP) for critical reading of this manuscript. This work was supported by a Research Growth Initiative Award from the University of Wisconsin–Milwaukee and an NIH/NCI grant R01 CA152212 (both to Y.-Q.C.). D.W. also acknowledges the NIH/NCI Intramural Research Program of the Center for Cancer Research for a fellowship support.

## ■ REFERENCES

- (1) Jones, P. A.; Baylin, S. B. *Cell* **2007**, *128*, 683–692.
- (2) Yoo, C. B.; Jones, P. A. *Nature Rev. Drug Discovery* **2006**, *5*, 37–50.
- (3) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. *Nature Rev. Drug Discovery* **2006**, *5*, 769–784.
- (4) Bots, M.; Johnstone, R. W. *Clin. Cancer Res.* **2009**, *15*, 3970–3977.
- (5) Lane, A. A.; Chabner, B. A. *J. Clin. Oncol.* **2009**, *27*, 5459–5468.
- (6) Schrupp, D. S. *Clin. Cancer Res.* **2009**, *15*, 3947–3957.
- (7) FDA. *J. Natl. Cancer Inst.* **2010**, *102*, 219.
- (8) Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. *Oncologist* **2007**, *12*, 1247–1252.
- (9) Wang, H.; Dymock, B. W. *Expert Opin. Ther. Pat.* **2009**, *19*, 1727–1757.
- (10) Ma, X.; Ezzeldin, H. H.; Diasio, R. B. *Drugs* **2009**, *69*, 1911–1934.
- (11) Okuhara, M.; Goto, T.; Hori, Y.; Fujita, T.; Ueda, H.; Shigematsu, N. U.S. Patent 4,977,138, 1990.
- (12) Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M. *J. Antibiot. (Tokyo)* **1994**, *47*, 301–310.
- (13) Masakuni, O.; Toshio, G.; Takashi, F.; Yasuhiro, H.; Hirotsugu, U. Japan Patent 3,141,296 (A), 1991.
- (14) Masuoka, Y.; Nagai, A.; Shin-ya, K.; Furihata, K.; Nagai, K.; Suzuki, K.; Hayakawa, Y.; Seto, H. *Tetrahedron Lett.* **2001**, *42*, 41–44.
- (15) Cheng, Y.-Q.; Wang, C. *Histone deacetylase inhibitors and uses thereof*. U.S. Patent Application 20110060021, 2011.
- (16) Biggins, J. B.; Gleber, C. D.; Brady, S. F. *Org. Lett.* **2011**, *13*, 1536–1539.
- (17) Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K. H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. *Cancer Res.* **2002**, *62*, 4916–4921.
- (18) Fischbach, M. A.; Walsh, C. T. *Chem. Rev.* **2006**, *106*, 3468–3496.
- (19) Finking, R.; Marahel, M. A. *Annu. Rev. Microbiol.* **2004**, *58*, 453–488.



- (20) Walsh, C. T.; Fischbach, M. A. *J. Am. Chem. Soc.* **2010**, *132*, 2469–2493.
- (21) Cheng, Y.-Q.; Yang, M.; Matter, A. M. *Appl. Environ. Microbiol.* **2007**, *73*, 3460–3469.
- (22) Wang, C.; Wesener, S. R.; Zhang, H.; Cheng, Y.-Q. *Chem. Biol.* **2009**, *16*, 585–593.
- (23) Newman, D. J.; Cragg, G. M. *J. Nat. Prod.* **2007**, *70*, 461–477.
- (24) Cragg, G. M.; Grothaus, P. G.; Newman, D. J. *Chem. Rev.* **2009**, *109*, 3012–3043.
- (25) Baltz, R. H. *SIM News* **2005**, 186–196.
- (26) Li, M. H.; Ung, P. M.; Zajkowski, J.; Garneau-Tsodikova, S.; Sherman, D. H. *BMC Bioinf.* **2009**, *10*, 185.
- (27) Corre, C.; Challis, G. L. *Nature Prod. Rep.* **2009**, *26*, 977–986.
- (28) Shoemaker, R. H. *Nature Rev. Cancer* **2006**, *6*, 813–823.
- (29) Monga, M.; Sausville, E. A. *Leukemia* **2002**, *16*, 520–526.
- (30) Potharla, V. Y.; Wesener, S. R.; Cheng, Y.-Q. *Appl. Environ. Microbiol.* **2011**, *77*, 1508–1511.
- (31) Wesener, S. R.; Potharla, W. Y.; Cheng, Y.-Q. *Appl. Environ. Microbiol.* **2011**, *77*, 1501–1507.
- (32) Kim, H. S.; Schell, M. A.; Yu, Y.; Ulrich, R. L.; Sarria, S. H.; Nierman, W. C. *BMC Genomics* **2005**, *6*, 174.
- (33) Lambalot, R. H.; Gehring, A. M.; Flugel, R. S.; Zuber, P.; LaCelle, M.; Marahiel, M. A.; Reid, R.; Khosla, C.; Walsh, C. T. *Chem. Biol.* **1996**, *3*, 923–936.
- (34) Cheng, Y.-Q.; Tang, G. L.; Shen, B. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 3149–3154.
- (35) Choi, K. H.; Schweizer, H. P. *BMC Microbiol.* **2005**, *5*, 30.
- (36) Caboche, S.; Leclere, V.; Pupin, M.; Kucherov, G.; Jacques, P. *J. Bacteriol.* **2010**, *192*, 5143–5150.
- (37) Wegener, D.; Hildmann, C.; Riester, D.; Schwienhorst, A. *Anal. Biochem.* **2003**, *321*, 202–208.
- (38) Bertos, N. R.; Wang, A. H.; Yang, X. J. *Biochem. Cell. Biol.* **2001**, *79*, 243–252.
- (39) Zhao, X.; Sternsdorf, T.; Bolger, T. A.; Evans, R. M.; Yao, T. P. *Mol. Cell. Biol.* **2005**, *25*, 8456–8464.
- (40) Vega, R. B.; Matsuda, K.; Oh, J.; Barbosa, A. C.; Yang, X.; Meadows, E.; McAnally, J.; Pomajzl, C.; Shelton, J. M.; Richardson, J. A.; Karsenty, G.; Olson, E. N. *Cell* **2004**, *119*, 555–566.
- (41) Cadot, B.; Brunetti, M.; Coppari, S.; Fedeli, S.; de Rinaldis, E.; Dello Russo, C.; Gallinari, P.; De Francesco, R.; Steinkuhler, C.; Filocamo, G. *Cancer Res.* **2009**, *69*, 6074–6082.
- (42) Guenther, M. G.; Barak, O.; Lazar, M. A. *Mol. Cell. Biol.* **2001**, *21*, 6091–6101.
- (43) A version of this paper had been submitted to another ACS journal for consideration on February 15, 2011, but after consideration it was decided that *J. Nat. Prod.* would be a more appropriate journal for publication of our results.
- (44) Brett, P. J.; DeShazer, D.; Woods, D. E. *Int. J. Syst. Bacteriol.* **1998**, *48* (Pt 1), 317–320.
- (45) Sambrook, J.; Russell, D. W., *Molecular Cloning: A Laboratory Manual*, 3rd ed.; Cold Spring Harbor Laboratory Press: New York, 2000.
- (46) Volund, A. *Biometrics* **1978**, *34*, 357–365.
- (47) Marquardt, D. M. *SIAM J. Appl. Math.* **1963**, *11*, 431–441.
- (48) Levenberg, K. Q. *Appl. Math.* **1944**, *2*, 164–168.
- (49) Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. *J. Natl. Cancer Inst.* **1989**, *81*, 1088–1092.
- (50) Holbeck, S. L.; Collins, J. M.; Doroshow, J. H. *Mol. Cancer Ther.* **2010**, *9*, 1451–1460.